Current approaches in the transcriptional-guided gene therapy of human hepatocellular carcinoma

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 4, 2007, Pages 378-384

  Hui, Kam M ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Adenovirus; Gene therapy; Hepatocellular carcinoma; siRNA

Indexed keywords

6 METHYLPURINE; 6 METHYLPURINE 2 DEOXYRIBOSIDE; ADENOVIRUS VECTOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBOXYPEPTIDASE G2; CHOLESTEROL DERIVATIVE; E1A PROTEIN; ENDOSTATIN; GANCICLOVIR; INTERLEUKIN 12; INTERLEUKIN 24; LIPOSOME; MELITTIN; ONCOLYTIC ADENOVIRUS; PURINE NUCLEOSIDE PHOSPHORYLASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; THYMIDINE KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ABSENCE OF SIDE EFFECTS; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DRUG FORMULATION; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR GENETICS; NONHUMAN; NONVIRAL GENE THERAPY; PHENOTYPE; REVIEW; SYMPTOM; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; LIVER; LIVER NEOPLASMS; PRODRUGS; TRANSCRIPTION, GENETIC;

ADENOVIRIDAE;

EID: 34547874593     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Kirk GD, Bah E, Montesano R: Molecular epidemiology of human liver cancer: Insights into etiology, pathogenesis and prevention from The Gambia, West Africa. Carcinogenesis (2006) 27(10):2070-2082.
2. Thomas MB, Abbruzzese JL: Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol (2005) 23(31):8093- 8108.
3. Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer (2006) 6(9):674-687.
4. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN et al: A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol (2004) 130(4):187-196.
5. Laurent-Puig P, Zucman-Rossi J: Genetics of hepatocellular tumors. Oncogene (2006) 25(27):3778-3786.
6. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D et al: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 125(7):1253-1267.
7. Fisher PB: Is mda-7/IL-24 a "magic bullet" for cancer? Cancer Res (2005) 65(22):10128-10138.
8. Wang CJ, Xue XB, Yi JL, Chen K, Zheng JW, Wang J, Zeng JP, Xu RH: Melanoma differentiation-associated gene-7, MDA-7/IL-24, selectively induces growth suppression, apoptosis in human hepatocellular carcinoma cell line HepG2 by replicationincompetent adenovirus vector. World J Gastroenterol (2006) 12(11):1774-1779.
9. Zhu DE, Hoti N, Song Z, Jin L, Wu Z, Wu Q, Wu M: Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model. Cancer Gene Ther (2006) 13(8):762-770.
10. Ye Z, Wang X, Hao S, Zhong J, Xiang J, Yang J: Oncolytic adenovirus-mediated E1A gene therapy induces tumor-cell apoptosis and reduces tumor angiogenesis leading to inhibition of hepatocellular carcinoma growth in animal model. Cancer Biother Radiopharm (2006) 21(3):225-234.
11. Son G, Hirano T, Seki E, Iimuro Y, Nukiwa T, Matsumoto K, Nakamura T, Fujimoto J: Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J Hepatol (2006) 45(5):688-695.
12. Heideman DA, Overmeer RM, van Beusechem VW, Lamers WH, Hakvoort TB, Snijders PJ, Craanen ME, Offerhaus GJ, Meijer CJ, Gerritsen WR: Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. Cancer Gene Ther (2005) 12(12):954-962.
13. Ribatti D, Vacca A, Nico B, Sansonno D, Dammacco F: Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev (2006) 32(6):437-444.
14. Lee K, Yun ST, Kim YG, Yoon Y, Jo EC: Adeno-associated virus-mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice. Hepatology (2006) 43(5):1063-1073.
15. Graepler F, Verbeek B, Graeter T, Smirnow I, Kong HL, Schuppan D, Bauer M, Vonthein R, Gregor M, Lauer UM: Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC. Hepatology (2005) 41(4):879-886. • A method to improve gene therapy efficacy through the interaction of two agents to give significant synergistic effects to treat HCC is described.
16. Ma H, Liu Y, Liu S, Xu R, Zheng D: Oral adeno-associated viruss-TRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatol (2005) 42(6):1355-1363.
17. Ren XW, Liang M, Meng X, Ye X, Ma H, Zhao Y, Guo J, Cai N, Chen HZ, Ye SL, Hu F: A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Cancer Gene Ther (2006) 13(2):159-168.
18. Miao J, Chen GG, Chun SY, Yun JP, Chak EC, Ho RL, Lai PB: Adenovirus-mediated tBid overexpression results in therapeutic effects on p53-resistant hepatocellular carcinoma. Int J Cancer (2006) 119(8):1985-1993.
19. Lemken ML, Wybranietz WA, Schmidt U, Graepler F, Armeanu S, Bitzer M, Lauer UM: Expression liver-directed genes by employing synthetic transcriptional control units. World J Gastroenterol (2005) 11(34):5295-5302.
20. Cho-Rok J, Yoo J, Jang YJ, Kim S, Chu IS, Yeom YI, Choi JY, Im DS: Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatol (2006) 43(5):1042-1052.
21. Sangkhathat S, Kusafuka T, Miao J, Yoneda A, Nara K, Yamamoto S, Kaneda Y, Fukuzawa M: In vitro RNA interference against β-catenin inhibits the proliferation of pediatric hepatic tumors. Int J Oncol (2006) 28(3):715-722.
22. Zhang PH, Zou L, Tu ZG: RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J Surg Res (2006) 131(1):143-149.
23. Wirth T, Kuhnel F, Fleischmann-Mundt B, Woller N, Djojosubroto M, Rudolph KL, Manns M, Zender L, Kubicka S: Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res (2005) 65(16):7393-7402. •• An HCC-specific gene therapy approach that could potentially overcome the chemoresistance of HCC is described.
24. Roderfeld M, Weiskirchen R, Wagner S, Berres ML, Henkel C, Grotzinger J, Gressner AM, Matern S, Roeb E: Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J (2006) 20(3):444-454. • An example of the prevention of HCC by treating chronic liver disease, a major risk for HCC, is provided.
25. Guan M, Rodriguez-Madoz JR, Alzuguren P, Gomar C, Kramer MG, Kochanek S, Prieto J, Smerdou C, Qian C: Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector. Cancer Res (2006) 66(3):1620-1629.
26. Shin D, Kim SI, Kim M, Park M: Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice. Virus Res (2006) 119(2):146-153.
27. Hou W, Ni Q, Wo J, Li M, Liu K, Chen L, Hu Z, Liu R, Hu M: Inhibition of hepatitis B virus X gene expression by 10-23 DNAzymes. Antiviral Res (2006) 72(3):190-196.
28. Yi J, Gong WD, Wang L, Ling R, Chen JH, Yun J: VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication. World J Gastroenterol (2005) 11(41):6429-6432.
29. Cao L, Si J, Wang W, Zhao X, Yuan X, Zhu H, Wu X, Zhu J, Shen G: Intracellular localization and sustained prodrug cell killing activity of TAT-HSVTK fusion protein in hepatocellular carcinoma cells. Mol Cells (2006) 21(1):104-111.
30. Schepelmann S, Hallenbeck P, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Hay C, Hawkins LK, Marais R, Springer CJ: Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res (2005) 65(12):5003-5008. • An approach to apply adenoviral vectors for HCC-targeted prodrug therapy is described.
31. Ling CQ, Li B, Zhang C, Zhu DZ, Huang XQ, Gu W, Li SX: Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma. Ann Oncol (2005) 16(1):109-115.
32. Cai X, Zhou J, Lin J, Sun X, Xue X, Li C: Experimental studies on PNP suicide gene therapy of hepatoma. J Huazhong Univ Sci Technolog Med Sci (2005) 25(2):178-181.
33. Cao L, Shen G, Zhu Y, Wang W, Zhao X, Ye Q, Zhu H, Lu Z, Si J: Characterization of a single-chain variable fragment (scFv) antibody directed against the human asialoglycoprotein receptor. Biotechnol Appl Biochem (2006) 44(2):65-72.
34. Sun X, Hai L, Wu Y, Hu HY, Zhang ZR: Targeted gene delivery to hepatoma cells using galactosylated liposome-polycation-DNA complexes (LPD). J Drug Target (2005) 13(2):121-128. •• The design of synthetic molecular delivery vehicles for the targeted gene therapy of HCC is described.
35. Wakabayashi K, Saito H, Kaneko F, Nakamoto N, Tada S, Hibi T: Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor. Int J Oncol (2005) 26(1):233-239.
36. Brombacher F, Kastelein RA, Alber G: Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol (2003) 24(4):207-212.
37. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, Benito A, Larrache J, Pueyo J, Subtil J, Olague C et al: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 22(8):1389-1397. •• This study provides a good example of a clinical trial using an Ad vector for gene therapy of HCC.
38. Menne S, Cote PJ: The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol (2007) 13(1):104-24.